← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
fexuprazan
A02BC10
Forms & Strengths
- 10 mg, 20 mg tablets
- 10 mg/10 mL oral suspension
- 20 mg/2 mL solution for injection
Adult Dosing
- 20-40 mg once daily for gastroesophageal reflux disease
- 10-20 mg once daily for NSAID-associated ulcer prophylaxis
- 20-40 mg twice daily for Zollinger-Ellison syndrome
Pediatric Dosing
- 1-2 mg/kg/day for erosive esophagitis in pediatric patients 1-11 years old
- 10-20 mg once daily for gastroesophageal reflux disease in pediatric patients 12 years and older
Indications
- Gastroesophageal reflux disease
- Zollinger-Ellison syndrome
- Erosive esophagitis
- NSAID-associated gastric or duodenal ulcer prophylaxis
Mechanism of Action
- Potassium-competitive acid blocker
- Inhibits gastric acid secretion by competitively blocking potassium channels on gastric parietal cells
Contraindications
- Hypersensitivity to fexuprazan or any component of the formulation
- Concomitant use with atazanavir or rilpivirine
Adverse Reactions
- Diarrhea
- Headache
- Abdominal pain
- Nausea
- Vitamin B12 deficiency with long-term use
Drug Interactions
- Atazanavir: decreases atazanavir plasma concentrations
- Rilpivirine: decreases rilpivirine plasma concentrations
- Ketoconazole and other CYP3A4 inhibitors: increases fexuprazan plasma concentrations
- Warfarin: increases international normalized ratio
Curated Content: Needs Vetting Before Put to Clinical Use